Program
BBT001
A development code.
Its studies are mostly in Dermatitis, Atopic · Chronic Urticaria, led by Bambusa Therapeutics.
Furthest: phase 2, since Jul 16, 20263 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bambusa Therapeutics | 33 open or running | phase 2since Jul 16, 2026 | Jan 30, 2025 | Feb 28, 2027phase 1 · NCT06808477 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2025First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06808477 · 237 planned · United States, Australia, New Zealand and more
- Sep 28, 2025Phase 1 study in Dermatitis, AtopicNCT07239947 · 99 planned · China
- Jul 16, 2026Phase 2 study in Chronic UrticariaPhase 2 reachedNCT07717905 · 48 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT06808477
- Dec 31, 2027Primary completion: phase 2 study in Chronic UrticariaNCT07717905
- Dec 31, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07239947
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07717905Chronic Urticaria · China | 2 | Recruiting | Dec 31, 2027 | 48 |
| NCT07239947Dermatitis, Atopic · China | 1 | Recruiting | Dec 31, 2027 | 99 |
| NCT06808477Dermatitis, Atopic · United States, Australia, New Zealand and more | 1 | Recruiting | Feb 28, 2027 | 237 |
How it is read
Names in the registry
- “BBT001”, 3 entries
Codes read as this program: BBT001.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.